On February 26, 2021 Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, reported a poster presentation on interim safety evaluation of same-day dosing of ROLONTIS (eflapegrastim) in patients with early-stage breast cancer receiving docetaxel and cyclophosphamide (Press release, Spectrum Pharmaceuticals, FEB 26, 2021, View Source [SID1234575772]). This presentation will take place as part of the 38th Annual Miami Breast Cancer Conference taking place virtually March 4-7, 2021. Details of the presentation are as follows:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Title: Interim safety evaluation of same-day dosing of eflapegrastim in patients with early-stage breast cancer (ESBC) receiving docetaxel and cyclophosphamide (TC)
Speaker: Lee S. Schwartzberg. M.D., FACP
Session: Poster Presentation
Date and Time: March 4, 2021, 6:00pm EST